Science incubator Labshares Newton is Set to Expand
Labshares News
Related or similar articles
March 26, 2019
Abcuro announces pre-clinical data on new immuno-oncology target
First in vivo validation of KLRG1 as a new cancer immunotherapy target
Member News
August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News